Delcath Systems Inc
Research Delcath Systems Inc (DCTH) on Bullrun: market cap USD 586.05M, P/E 2773.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDCTH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 586.05M
- P/E2773.8
- Financial periodQ2 2026
- RevenueUSD 29.13M
- Net incomeUSD 2.67M
- Free cash flowUSD 5.21M
- Gross margin89.8%
Valuation Snapshot
latest market cap is USD 586.05M; P/E is 2773.8.
Peer valuation comparison
Latest P/E is 2773.77x versus a Healthcare sector median of 24.46x (11240.1% above).
Latest P/E is 2773.77x versus a United States median of 24.87x (11054.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 85.23M | USD 2.70M | USD 20.97M | 86.2% | 0.07 | USD 43.45M | USD 936.00K | USD 111.22M |
| FY2024 | USD 37.21M | -USD 26.39M | -USD 19.24M | 83.4% | -0.93 | USD 32.41M | USD 0 | USD 68.75M |
| FY2023 | USD 2.07M | -USD 47.68M | -USD 31.31M | 69.2% | -2.94 | USD 12.65M | USD 10.15M | USD 15.78M |
| FY2022 | USD 2.72M | -USD 36.51M | -USD 25.16M | 74.8% | -4.12 | USD 7.67M | USD 15.69M | -USD 5.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 586.05M | 2773.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 350.39M | 168.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 398.05M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 91.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.17M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 61.28M | n/a | n/a | n/a |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Delcath Systems Inc's market cap?
Delcath Systems Inc's market capitalization is USD 586.05M.
What is Delcath Systems Inc's P/E ratio?
Delcath Systems Inc's price-to-earnings (P/E) ratio is 2773.8.
What does Delcath Systems Inc do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.